Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial

LESSONS LEARNED. First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post‐platinum metastatic urothelial cancer (mUC) patients. A recommended phase II dose was identified for the treatment combination of vinflunine plus so...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Carl‐Henrik, Pappot, Helle, Agerbæk, Mads, Holmsten, Karin, Jäderling, Fredrik, Yachnin, Jeffrey, Grybäck, Per, von der Maase, Hans, Ullén, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656519/
https://www.ncbi.nlm.nih.gov/pubmed/30552156
http://dx.doi.org/10.1634/theoncologist.2018-0795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656519/
https://www.ncbi.nlm.nih.gov/pubmed/30552156
http://dx.doi.org/10.1634/theoncologist.2018-0795

Ejemplares similares